Traumatic brain injury (TBI) affects millions of people worldwide every year and remains a major cause of long-term disability, cognitive decline, and neurological complications. Although neurons have historically received most attention in brain injury research, growing evidence shows that glial cells—microglia, astrocytes, and oligodendrocytes—play equally critical roles in determining whether the injured brain progresses toward degeneration or recovery. These non-neuronal cells regulate inflammation, protect neural circuits, maintain white matter integrity, and influence the brain's ability to repair itself after trauma.
Addressing this challenge, a research team led by Professor Kyoungho Suk from the Department of Pharmacology at the School of Medicine, Kyungpook National University, the Republic of Korea, comprehensively examined how glial cells interact, adapt, and communicate during different stages of traumatic brain injury. The researchers analyzed recent advances in glial biology, neuroinflammation, remyelination, and therapeutic modulation, focusing on how glial responses shift between protective and harmful states depending on injury severity and timing. Their findings were published on May 21, 2026, in the journal Brain Network Disorders .
The study highlights that glial cells do not function independently after TBI. Instead, they form highly dynamic communication networks that shape injury progression and tissue repair. Activated microglia release inflammatory molecules that can transform astrocytes into neurotoxic states, while astrocytes can also promote anti-inflammatory microglial responses and support neuronal survival. Oligodendrocytes, responsible for producing myelin around axons, are especially vulnerable to traumatic injury and inflammatory stress, leading to white matter degeneration and impaired neural signaling. The researchers emphasize that understanding this coordinated cellular behavior is essential for designing effective therapies.
Importantly, the review explains why many single-target therapies have struggled in clinical trials. Inflammation after TBI serves both beneficial and damaging functions. Acute inflammatory responses help clear debris and initiate repair, but excessive or persistent activation can worsen neuronal death, demyelination, and chronic neurodegeneration. According to the researchers, future treatments should therefore selectively modulate glial functions instead of broadly suppressing inflammation. Therapies must also account for distinct recovery windows, including acute neuroprotection, subacute tissue remodeling, and chronic remyelination.
The researchers also explored emerging therapeutic approaches that could improve white matter repair and functional recovery. One promising strategy involves stimulating oligodendrocyte precursor cells to regenerate damaged myelin. Existing FDA-approved drugs such as clemastine fumarate, originally developed as antihistamines, are now being investigated for their promyelinating effects. Other experimental approaches include modulating microglial activation states, enhancing astrocytic metabolic support, targeting inhibitory scar molecules, and promoting endogenous repair pathways instead of relying solely on transplanted cells.
"Glial cells are remarkably plastic and multifunctional. They can either protect or damage the brain depending on the surrounding microenvironment and injury stage," explains Prof. Suk. "Understanding these dynamic transitions is critical for developing therapies that preserve beneficial responses while limiting pathological activation."
Beyond therapeutic development, the findings could influence multiple research areas, including neurodegenerative disease, stroke, spinal cord injury, aging, and neuroimmunology. The researchers suggest that advanced single-cell transcriptomics and omics-based technologies may enable precision medicine strategies that identify specific pathological glial subpopulations in individual patients. Such approaches could improve biomarker discovery, patient stratification, and treatment responsiveness while encouraging interdisciplinary collaborations among neuroscientists, clinicians, pharmacologists, and bioengineers.
The study also outlines important societal implications. In the short term, a better understanding of glial biology may improve rehabilitation strategies and guide the development of treatments that reduce chronic inflammation, cognitive dysfunction, and white matter damage after TBI. Over longer timeframes, glia-targeted therapies could potentially reduce disability burdens, improve quality of life, and lower healthcare costs for patients experiencing long-term neurological complications.
"Traumatic brain injury should not be viewed solely as neuronal damage, but as a complex disorder involving coordinated interactions between brain cells and systemic responses," says Prof. Suk. "Future therapeutic success will likely depend on combination strategies that integrate glial modulation, regenerative medicine, and personalized interventions."
Overall, the researchers conclude that glial cells have moved from supporting agents to central regulators of injury and recovery after TBI. By recognizing the importance of cellular communication networks, temporal therapeutic windows, and precision-targeted interventions, the study provides a roadmap for future therapies that may transform clinical outcomes for patients affected by traumatic brain injury.
